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topics related to neurological and psychiatric disease.
The reviews were chosen to complement the topics
and talks to be presented at this year’s Neuron satellite
meeting on ‘‘Neurons and Disease’’ at the Society for
Neuroscience meeting (http://www.neuron-meeting.com)
on October 12th and 13th. The speakers at the meet-
ing will be Adriano Aguzzi, Mark Bear, Nancy Bonini,
David Porteous, Louis Ptacek, Jeffrey Rothstein,
Dennis Selkoe, Thomas Su¨dhof, Nora Volkow, and
Huda Zoghbi. We are still accepting registrations for
the meeting.
In considering potential topics for this series, there
was certainly no shortage of subject matter to choose
from. Tragically, there are far too many ways that the
complex machine that is our brain can go awry. Clearly,
we could not cover adequately every major disease or
even category of diseases in this series. The challenge
was to narrow down the possibilities to a focused group
of reviews. Our aim was to highlight the rich biology and
diversity of mechanisms that characterize diseases of
the nervous system, and we have selected topics that
we think illuminate common principles, mechanisms,
or approaches that go beyond a particular disease.
The reviews as a whole spotlight the challenges associ-
ated with unraveling disease mechanisms in an organ as
complicated as the brain and point to the importance of
integrating multiple types of approaches and multiple
levels of analyses to understanding disease.
November 3rd marks the 100th anniversary of the lec-
ture from Alois Alzheimer presenting the first case of
a patient with a neural pathological disease character-
ized by progressive dementia that came to be known
as Alzheimer’s disease. It seems fitting to pay tribute
to this event in this series. In his essay, ‘‘A Hundred
Years of Alzheimer’s Disease Research,’’ John Hardy re-
views the progress in the field in the intervening century
and suggests where the remaining challenges lie. Hardy
suggests that there have been three periods of Alz-
heimer’s research—the first led to the definition of the
clinical phenotype, the second involved a neurochemical
assessment of the disease, and the third, the current pe-
riod, is the application of molecular biological and ge-
netic approaches to investigate underlying mechanisms
with an ultimate goal of translating these mechanistic in-
sights into therapies. The review from Scott Small and
Sam Gandy also covers Alzheimer’s disease. Small
and Gandy argue that a cell biological understanding
of Alzheimer’s disease may be key to deciphering this
disease. Their review discusses recent results suggest-
ing a contribution of protein sorting pathways and defi-
cits to Alzheimer’s pathogenesis. Just as has been the
case for Alzheimer’s disease, for many of the more clas-
sical neurodegenerative diseases, such as Parkinson’s
disease, Huntington’s disease, ALS, and multiple scle-
rosis, genetics has been key to providing insights into
potential pathways and mechanisms, but cell biology
has been critical for building mechanistic models for
how these genes and pathways function in a biological
context. In their review, Virginia Lee and John Trojanow-ski discuss the mechansisms of a-synuclein-mediated
neurodegeneration and propose drug discovery ap-
proaches for identifying therapies that target a-synu-
clein. The formation of inclusion bodies and protein ag-
gregates that is the hallmark of a-synuclein pathologies
is turning out to be a common phenotype for a broad
range of disorders. Whether these inclusions play
a causal role in pathogenesis or are simply a marker of
the disease or are even a protective cellular mechanism
remains unclear.
Many classes of neurodegenerative diseases appear
to impact specific populations of neurons or regions of
the brain preferentially, and a key question is what
accounts for the selective vulnerability of certain classes
of neurons to certain pathologies. For example, ALS is
a disease that selectively impacts motor neurons. Se´-
verine Boille´e, Christine Vande Velde, and Don Cleve-
land review our current understanding of ALS pathogen-
esis and address this question in their review, arguing
that this selective vulnerability stems from a combination
of multiple mechanisms, involving not just the motor
neurons but also neighboring glia and other nonneuro-
nal cells, including cells of the immune system. Indeed,
as several of the reviews in the series highlight, while the
contribution of the immune system has been largely ig-
nored for many diseases of the CNS (or was thought to
be a marker and consequence of the disease, not
a causal element) there is increasing support for a role
of inflammation and immune mechanisms in many dis-
eases of the nervous system. For instance, it is clear
that inflammation and the immune response is a key
factor in multiple sclerosis, and in their review, Stephen
Hauser and Jorge Oksenberg review recent develop-
ments in understanding the etiology and disease patho-
genesis of multiple sclerosis, including the contribution
of the immune system. Recent work on multiple sclero-
sis also highlights this theme of interactions between
multiple cell types contributing to pathology. Multiple
sclerosis has long been thought to be a myelin disease.
However, there is now a large body of work to show that
damage to axons and neuronal loss precede the loss of
myelin and may play a key role in some of the neurolog-
ical dysfunctions associated with the disease. There is
also strong evidence to suggest a key role for the im-
mune system in neuropathic pain. James Campbell
and Richard Meyer review current understanding of
the the mechanisms of neuropathic pain, with a particu-
lar focus on peripheral nerve pathologies. Continuing on
the theme of immune contributions to diseases of the
nervous system, the review from Angela Vincent, Bethan
Lang, and Kleopas Kleopa on autoimmune channelopa-
thies discusses the role of autoantibodies in various
neurological diseases.
As many of the reviews in this series spotlight, molec-
ular genetics has proven to be a powerful tool for crack-
ing open many of these diseases. For diseases like
Alzheimer’s and Parkinson’s, some of the greatest in-
sights into disease pathogenesis have come from the
identification of genes associated with rare familial
forms of these diseases, which in turn shed light on
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member that genetic contributions can be more compli-
cated than point mutations, deletions, simple trunca-
tions, or simple Mendelian genetics. The review by
Jennifer Lee and James Lupski explores more complex
genomic mechanisms and their contribution to diseases
of the nervous system. Lee and Lupski discuss diseases
that are caused not by the classic type of genetic lesion
resulting in singular changes in the DNA sequence of
a particular coding region but rather are due to genomic
rearrangements that lead to a change in gene copy
number and dosage. The review from Donny Licatalosi
and Robert Darnell on the role of splicing regulation in
neurologic disease highlights another form of genomic
complexity—alternative splicing. There are more and
more examples of alternatively spliced mRNAs in the
nervous system, including alternatively spliced ion
channels, membrane receptors, and other regulatory
proteins. In most cases, the precise impact of the differ-
ent splice isoforms and their regulation on neuronal
function is only beginning to be understood.
Arguably, we have advanced more quickly in our un-
derstanding of the causes of neurodegenerative dis-
eases, like Alzheimer’s, Parkinson’s, multiple sclerosis,
ALS, Huntington’s, and other polyglutamine disorders,
than we have in deciphering psychiatric diseases, like
schizophrenia and depression, or complex neurodeve-
lopmental disorders, like autism. Both the complexity
of the clinical phenotypes of these diseases (which, in
most cases, are actually a spectrum of disorders rather
than a single disease) and the fact that these diseases
are multifactorial, involving many genes and multiple
systems, may contribute to the slower pace of discov-
ery. Christopher Ross, Russell Margolis, Sarah Reading,
Mikhail Pletnikov, and Joseph Coyle review recent prog-
ress in our understanding of schizophrenia, both with
respect to the clinical features of the disease and the
underlying neuropathologies. Schizophrenia, like many
psychiatric disorders, is a disease involving multiple
neural systems. There has been some data to suggest
that neuronal synchrony, the coordinated interactions
of networks of neurons across multiple brain regions,
may contribute to the cognitive impairments associated
with schizophrenia. The review from Peter Uhlhaas and
Wolf Singer discusses potential links between defects
in neural synchronization and the behavioral and
cognitive dysfunctions associated with disorders like
schizophrenia, epilepsy, autism, and Alzheimer’s and
Parkinson’s diseases.
Animal models have been a critical tool for under-
standing diseases of the nervous system, and two of
the reviews in this series discuss the contributions
that different types of animal models can have for bothdeciphering disease mechanisms and for assessing
therapeutics. Such models are not without major
caveats; quite obviously, neither the mouse brain nor
the Drosophila brain is a perfect model of the human
brain. In their review, P. Alexander Arguello and Joseph
Gogos discuss the challenges associated with develop-
ing models for psychiatric diseases like schizophrenia,
which encompass a complex disease phenotype and
etiology. J. Lawrence Marsh and Leslie Thompson dis-
cuss the contributions that lower invertebrate model
systems, like Drosophila, have made toward under-
standing neurodegenerative disease and the advan-
tages that Drosophila, with its ease of manipulation
and powerful genetics, offers both for dissecting dis-
ease mechanisms and for screening potential therapies.
The ultimate aim of all of the research into disease
mechanisms is to find a cure and to alleviate the tremen-
dous human suffering associated with each of these
diseases. Two reviews in this issue discuss two very
promising forms of therapy that even a few years ago
might have been thought to be futuristic and more
science fiction than practical reality. Thomas Wichmann
and Mahlon DeLong discuss the potentials of deep brain
stimulation as a therapeutic approach for movement
disorders and some classes of psychiatric diseases.
Andrew Schwartz, Tracy Cui, Douglas Weber, and
Daniel Moran discuss the potential applications for
neural prosthetics for the treatment of motor disorders.
The goal of this review series is to highlight the sig-
nificant advances in understanding diseases of the
nervous system that have been made in recent years.
We hope that we have been able to capture the excite-
ment in the field and that you will find these reviews in-
teresting and informative. There is still much we don’t
know and much work to be done, but there are reasons
to be optimistic.
We are grateful for the efforts of all of the authors in
this series and also the anonymous reviewers who pro-
vided feedback on the reviews. To close, we would like
to say a few words about the cover art, which is an ad-
aptation of an oil painting by Bryan Charnley, an artist
who suffered from paranoid schizophrenia. The painting
is entitled Self Portrait, 6thMay 1991 and is from a series
of pieces that he painted during a period of time while
experimenting with varying dosages of the drugs used
to control his disease. We would like to thank the UK-
based mental health charity SANE and the family of the
artist for granting permission to use this image for the
cover art. The painting beautifully depicts the tragedy
and disarray associated with this disease, and the ques-
tion mark at the center of the bulls-eye target on the
artist/subject’s head speaks loudly for the many ques-
tions and challenges that still remain in this field.
